RESUMO
The aim of the study was to assess the combined effects of chromium(III) supplementation and iron deficiency on the copper (Cu) and zinc (Zn) status in female rats. The Cr, Fe, Cu and Zn dietary and tissular levels were measured by Atomic Absorption Spectrometry (AAS) method. The data show that chromium(III) supplementation compensated for the negative effects of Fe deficiency on the Cu content but it deepened the effect on Zn levels in the female rats. Detailed data on the status of trace elements and their interactions in healthy subjects and patients with metabolic disorders (e.g. anaemia, diabetes mellitus) are strongly required for effective nutritional and therapeutic strategies.
Assuntos
Anemia Ferropriva/tratamento farmacológico , Compostos de Cromo/uso terapêutico , Cobre/uso terapêutico , Compostos Férricos/uso terapêutico , Zinco/uso terapêutico , Anemia Ferropriva/metabolismo , Animais , Peso Corporal , Compostos de Cromo/administração & dosagem , Cobre/administração & dosagem , Suplementos Nutricionais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Ingestão de Alimentos/efeitos dos fármacos , Feminino , Compostos Férricos/administração & dosagem , Ratos , Ratos Wistar , Relação Estrutura-Atividade , Zinco/administração & dosagemRESUMO
Psychopharmacologic treatment is playing a greater role in the management of patients with eating disorders. In this paper, we review randomized, placebo-controlled trials (RCTs) conducted in anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), and other eating disorders over the past 3 years. Fluoxetine remains the only medication approved for an eating disorder, that being BN. RCTs of antipsychotics in AN have had mixed results; the only agent with some evidence of efficacy is olanzapine. One study suggests dronabinol may induce weight gain in AN. Preliminary studies suggest lack of efficacy of alprazolam, dehydroepiandrosterone, or physiologic estrogen replacement in AN; erythromycin in BN; and the opioid antagonist ALKS-33 in BED. In BED with obesity or overweight, bupropion may cause mild weight loss without seizures, and chromium may improve glucose regulation. Also in BED, three RCTs suggest the stimulant prodrug lisdexamfetamine may reduce binge eating episodes, and another RCT suggests intranasal naloxone may decrease time spent binge eating. There remains a disconnection between the size of eating disorders as a public health problem and the lack of pharmacotherapy research of these conditions.
Assuntos
Anorexia Nervosa/tratamento farmacológico , Fármacos Antiobesidade/uso terapêutico , Antidepressivos de Segunda Geração/uso terapêutico , Antipsicóticos/uso terapêutico , Transtorno da Compulsão Alimentar/tratamento farmacológico , Bulimia Nervosa/tratamento farmacológico , Bupropiona/uso terapêutico , Estimulantes do Sistema Nervoso Central/uso terapêutico , Morfinanos/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Obesidade/prevenção & controle , Administração Intranasal , Baclofeno/uso terapêutico , Transtorno da Compulsão Alimentar/complicações , Bulimia Nervosa/complicações , Compostos de Cromo/uso terapêutico , Humanos , Dimesilato de Lisdexanfetamina/uso terapêutico , Naloxona/administração & dosagem , Obesidade/etiologia , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Diabetes, particularly type II diabetes, is a severe disease condition which affects human health worldwide, with a dramatically increasing trend in Asian countries including China. Currently, no efficient drugs other than those with observable side effects are available. Chromium complexes, with the most known representative chromium picolinate, have been listed as one of most attractive health supplements to attenuate this disease condition in western countries. Recent efforts have been made to develop new chromium complexes with novel ligands. Although fair amounts of reviews have been published to emphasize the biological activity, preclinical and clinical information of chromium picolinate, this mini-review is trying to cover the entire picture of updated research efforts on various chromium complexes highlighting the role of ligands. Chromium phenylalanine sensitizes insulin cell signaling pathway via the activation of phosphorylation of Akt (protein kinase B (PKB)) and/or AMPK (AMP-activated protein kinase). The biological activities, toxicity, pharmacological features and clinical implications, including the effect of anti-oxidative capacities, protective effect on obese-induced heart dysfunction, and efficacy and safety of chromium supplementation in diabetes are discussed as well.
Assuntos
Compostos de Cromo/farmacologia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/farmacologia , Compostos Organometálicos/farmacologia , Proteínas Quinases Ativadas por AMP/metabolismo , Animais , Compostos de Cromo/química , Compostos de Cromo/uso terapêutico , Diabetes Mellitus Tipo 2/metabolismo , Humanos , Hipoglicemiantes/química , Hipoglicemiantes/uso terapêutico , Compostos Organometálicos/química , Compostos Organometálicos/uso terapêutico , Proteínas Proto-Oncogênicas c-akt/metabolismoRESUMO
PURPOSE: (32)P-chromic phosphate colloid treatments of astrocytoma and craniopharyngioma cystic brain tumours in paediatric patients are conventionally based on a sphere model under the assumption of uniform uptake. The aims of this study were to determine the distribution of the absorbed dose delivered by (32)P on a patient-specific basis and to evaluate the accuracy with which this can be predicted from a pretherapy administration of (99m)Tc-Sn colloid. METHODS: Three patients were treated with (32)P-chromic phosphate colloid following (99m)Tc-Sn colloid administrations. Convolution dosimetry was performed using pretherapy and posttherapy sequential SPECT imaging, and verified with EGSnrc Monte Carlo radiation transport simulations. Mean absorbed doses to the cyst wall and dose-volume histograms were also calculated and compared with those obtained by the sphere model approach. RESULTS: Highly nonuniform uptake distributions of both the (99m)Tc and (32)P colloids were observed and characterized by dose-volume histograms to the cyst wall. Mean absorbed doses delivered to the cyst wall, obtained with the convolution method, were on average 21 % (SD 18 %) and 50 % (SD 30 %) lower than those predicted by the (99m)Tc distribution and the uniform assumption of the sphere model, respectively. CONCLUSION: Absorbed doses delivered to the cyst wall by (32)P are more accurately predicted from image-based patient-specific convolution dosimetry than from simple sphere models. These results indicate the necessity to perform personalized treatment planning and verification for intracavitary irradiation of cystic brain tumours treated with radiocolloids. Patient-specific dosimetry can be used to guide the frequency and levels of repeated administrations and would facilitate data collection and comparison to support the multicentre trials necessary to progress this therapy.
Assuntos
Astrocitoma/radioterapia , Neoplasias Encefálicas/radioterapia , Compostos de Cromo/farmacocinética , Craniofaringioma/radioterapia , Fosfatos/farmacocinética , Neoplasias Hipofisárias/radioterapia , Radiometria , Compostos Radiofarmacêuticos/farmacocinética , Astrocitoma/diagnóstico por imagem , Neoplasias Encefálicas/diagnóstico por imagem , Criança , Compostos de Cromo/uso terapêutico , Coloides/farmacocinética , Coloides/uso terapêutico , Craniofaringioma/diagnóstico por imagem , Cistos/diagnóstico por imagem , Cistos/radioterapia , Relação Dose-Resposta a Droga , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Modelos Biológicos , Fosfatos/uso terapêutico , Neoplasias Hipofisárias/diagnóstico por imagem , Compostos de Tecnécio/farmacocinética , Compostos de Tecnécio/uso terapêutico , Compostos de Estanho/farmacocinética , Compostos de Estanho/uso terapêutico , Tomografia Computadorizada de Emissão de Fóton ÚnicoRESUMO
The study goal was to clarify the therapeutic effect and the absorbed dose of radionuclide phosphorus-32 for skin hemangiomas and the consequent risk of side effects in these patients. Phosphorus-32 is an ß emitter and is used for skin hemangioma treatment. In comparison with the few Gy per minute of the linear accelerators, the dose rate of phosphorus-32 for hemangiomas is much <1 Gy/hour; so, the latter is called low-dose-rate radiation. To achieve the therapeutic dose, continuous hours or days of radiation is necessary. For strawberry hemangiomas, the phosphorus-32 applicator was tightly placed on the lesion site for several hours until reaching therapeutic dose. The absorbed dose was estimated by radiochromic films. The absorbed dose of phosphorus-32 irradiation declined exponentially with a depth from 0 to 2.5 mm. Of the 316 patients with strawberry hemangiomas, the lesion disappeared completely within 3 months after one-time treatment in 259 cases (82%). For cavernous hemangiomas, 370KBq phosphorus-32 colloid was injected into the hemangioma each square centimeter, and the absorbed radiation was estimated by theoretical calculation. Forty-two of the 58 patients with cavernous hemangiomas (72%) had lesions that completely disappeared within 3 months after receiving one to six treatments. Thus, the phosphorus-32 for strawberry hemangiomas and the chromium phosphate-32 colloid for cavernous hemangiomas were clearly efficacious.
Assuntos
Hemangioma Cavernoso/radioterapia , Radioisótopos de Fósforo/administração & dosagem , Neoplasias Cutâneas/radioterapia , Adolescente , Adulto , Compostos de Cromo/uso terapêutico , Relação Dose-Resposta à Radiação , Feminino , Humanos , Lactente , Masculino , Prognóstico , Dosagem Radioterapêutica , Adulto JovemRESUMO
BACKGROUND AND OBJECTIVE: ³²P-chromic phosphate-poly (L-lactic) acid (³²P-CP-PLLA) microparticle is a novel potent brachytherapy implant, which has good biocompatibility and biodegradability. The aim of this study is to investigate the changes of pathology and PET/CT images in VX2 rabbit tumor after treatment with intratumorol administration of ³²P-CP-PLLA microparticles, and to explore the effects and influence of tumor growth and apoptosis related proteins in VX2 lung tumor treatment with ³²P-CP-PLLA microparticles. METHODS: Twenty-four tumor bearing rabbits were randomly divided into 4 groups (6 in each group). Group 1, 2 and 3 were treated groups; group 4 was the control. Under CT guidance, ³²P-CPPLLA microparticles were implanted into tumors. Low, medium and high treatment doses were 93 MBq (group 1), 185 MBq (group 2) and 370 MBq (group 3), respectively. ¹8F-FDG PET/CT was performed at d0, d3, d7 and d14 after intratumoral administration. In the control group, ¹8F-FDG PET/CT images were acquired at the same time points but without treatment. The standardized uptake value (SUV) of tumor regions were calculated. After last PET/CT imaging, the rabbits were euthanized and the tumors were removed for histological and immunohistochemical examination. The pathology and the expression of apoptosis related proteins (bcl-2, bax) were compared. RESULTS: No significant difference of SUVmax was observed between the treatment groups and the control group at d0. At d14, the SUVmax values for group 1, 2 and 3 were 0.80±0.10, 1.1±0.19 and 2.85±0.15, respectively, and were significantly lower than that of the control group (5.61±0.50)(P < 0.05). Significant dose-response relationship was observed in SUVmax between group 1 and group 2, and the SUV values gradually decreased from d7 to d14 after treatment. In group 3, SUVmax gradually increased and reached a peak at d7 then significantly decreased. The SUVmax values of group 3 were significantly lower than those of the control at the same time point (P < 0.05). HE staining found degenerative necrosis at the site was nearby the microparticle. Necrosis became serious increasing with the radioactivity. Inflammatory cell infiltration was rarely seen in tumors treated with 93 MBq or 185 MBq ³²P-CP-PLLA microparticles. In contrast, the necrotic area was surrounded by marked inflammatory cell infiltration in group 3. IHC analysis showed that the expression of bcl-2 in treated groups were lower than those in the control group, and the expression of bax in treated group was higher than those in the control group (P < 0.05). The ratio of bcl-2/bax protein significantly decreased in the treated group (P < 0.05). Dose dependence was seen in the expression of apoptosis related proteins. CONCLUSIONS: The sustained irradiation of ³²P-CP-PLLA microparticles can direct kill the VX2 tumor cell, thus the glycolysis of which were suppressed. Although the alive tumor cells still presented faraway from the microparticle, the expression of apoptosis related proteins in which were significantly different from the control. Bcl-2 and bax gene were induced to participate in regulation for the apoptosis of VX2 tumor cell by ionizing radiation from ³²P-CP-PLLA microparticles, so that the tumor growth was inhibited.
Assuntos
Braquiterapia , Compostos de Cromo/uso terapêutico , Neoplasias Pulmonares/diagnóstico por imagem , Neoplasias Pulmonares/radioterapia , Fosfatos/uso terapêutico , Radioisótopos de Fósforo/uso terapêutico , Animais , Apoptose/efeitos da radiação , Modelos Animais de Doenças , Feminino , Fluordesoxiglucose F18/administração & dosagem , Humanos , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/fisiopatologia , Masculino , Tomografia por Emissão de Pósitrons , Coelhos , Distribuição Aleatória , Tomografia Computadorizada por Raios XRESUMO
Intracavitary injections of (32)P chromic phosphate are used in the therapy of pleuropulmonary blastoma and pulmonary sarcomas in children. The lung dose, however, has never been calculated despite the potential risk of lung toxicity from treatment. In this work the dosimetry has been calculated in target tissue and lung for pediatric phantoms. Pleural cavities were modeled in the Monte Carlo code MCNP within the pediatric MIRD phantoms. Both the depth-dose curves in the pleural lining and into the lung as well as 3D dose distributions were calculated for either homogeneous or inhomogeneous (32)P activity distributions. Dose-volume histograms for the lung tissue and isodose graphs were generated. The results for the 2D depth-dose curve to the pleural lining and tumor around the pleural cavity correspond well with the point kernel model-based recommendations. With a 2 mm thick pleural lining, one-third of the lung parenchyma volume gets a dose more than 30 Gy (V(30)) for 340 MBq (32)P in a 10 year old. This is close to lung tolerance. Younger children will receive a larger dose to the lung when the lung density remains equal to the adult value; the V(30) relative lung volume for a 5 year old is 35% at an activity of 256 MBq and for a 1 year old 165 MBq yields a V(30) of 43%. At higher densities of the lung tissue V(30) stays below 32%. All activities yield a therapeutic dose of at least 225 Gy in the pleural lining. With a more normal pleural lining thickness (0.5 mm instead of 2 mm) the injected activities will have to be reduced by a factor 5 to obtain tolerable lung doses in pediatric patients. Previous dosimetry recommendations for the adult apply well down to lung surface areas of 400 cm(2). Monte Carlo dosimetry quantitates the three-dimensional dose distribution, providing a better insight into the maximum tolerable activity for this therapy.
Assuntos
Compostos de Cromo/administração & dosagem , Compostos de Cromo/efeitos adversos , Pulmão/efeitos da radiação , Órgãos em Risco/efeitos da radiação , Fosfatos/administração & dosagem , Fosfatos/efeitos adversos , Cavidade Pleural/efeitos da radiação , Adulto , Fatores Etários , Criança , Pré-Escolar , Compostos de Cromo/uso terapêutico , Humanos , Lactente , Injeções , Pulmão/patologia , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/radioterapia , Modelos Biológicos , Método de Monte Carlo , Órgãos em Risco/patologia , Imagens de Fantasmas , Fosfatos/uso terapêutico , Pleura/patologia , Pleura/efeitos da radiação , Cavidade Pleural/patologia , Blastoma Pulmonar/patologia , Blastoma Pulmonar/radioterapia , Doses de Radiação , Radiometria , Sarcoma/patologia , Sarcoma/radioterapiaRESUMO
OBJECTIVE: The purpose of our study was to retrospectively examine the efficacy of intralesional injection of 32P chromic phosphate, a beta-emitting colloidal radiopharmaceutical, in the treatment of aneurysmal bone cysts of the axial skeleton. Five patients with large aneurysmal bone cysts were managed with injection of 32P chromic phosphate into their tumors under CT guidance. With only a single minor complication, all lesions were observed to ossify on follow-up CT, with an average follow up of 2 years. CONCLUSION: CT-guided injection of axial aneurysmal bone cysts with 32P chromic phosphate leads to excellent local lesion control. In addition, the morbidity associated with this procedure is lower than that associated with surgical or other nonsurgical treatments.
Assuntos
Cistos Ósseos Aneurismáticos/radioterapia , Compostos de Cromo/uso terapêutico , Fosfatos/uso terapêutico , Radioisótopos de Fósforo/uso terapêutico , Compostos Radiofarmacêuticos/uso terapêutico , Adolescente , Cistos Ósseos Aneurismáticos/diagnóstico por imagem , Criança , Feminino , Humanos , Injeções Intralesionais , Masculino , Radiografia Intervencionista , Estudos Retrospectivos , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Adulto JovemRESUMO
OBJECTIVE: We aimed to study the interstitial injection of (32)P-chromic phosphate colloids ((32)P-CP) during lung cancer resection to treat occult lymphatic metastasis, and to observe its medium-term and long-term effects. METHODS: Seventy-three patients underwent surgery combined with injection of (32)P-CP with the dosage of 296-370 MBq/10 ml to the adipose and connective tissues neighboring pulmonary hilum, superior mediastinum, carina of trachea, and suspicious invaded pleura. Fifty-eight patients underwent only tumor resections served as control group. A monofactorial analysis by a chi test was conducted to determine the differences in positive rates of lymph nodes, the incidence of complications after the operation, the rate of supraclavicular lymph node metastasis, and the survival rate between the two groups. The survival curves were obtained using the Kaplan-Meier method and were compared by a log-rank test. The Cox's multivariate analysis was performed to identify the prognostic factors. RESULTS: There was no significant difference between lymph node-positive rates and the incidences of major complications (P>0.05). The rate of supraclavicular lymph node metastasis in surgery plus (32)P-CP group was prominently lower than that in the control group (P<0.05). Three-year and 5-year survival rates of the two groups showed significant difference (P<0.05). A Kaplan-Meier analysis revealed prominent statistical differences between the two groups (P<0.05). The Cox's multivariate analysis showed that the injection of (32)P-CP is one of the independent predictors of survival rates. CONCLUSION: Interstitial mediation with (32)P-CP during the resection of lung cancer is effective in inhibiting postoperative occult lymphatic metastasis, and showed satisfactory effects in improving patients' medium-term and long-term survival rates.
Assuntos
Compostos de Cromo/administração & dosagem , Compostos de Cromo/uso terapêutico , Líquido Extracelular , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/cirurgia , Metástase Linfática/prevenção & controle , Fosfatos/administração & dosagem , Fosfatos/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Superfície Corporal , Feminino , Humanos , Injeções , Complicações Intraoperatórias , Excisão de Linfonodo , Metástase Linfática/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Doses de Radiação , Taxa de Sobrevida , Resultado do TratamentoRESUMO
BACKGROUND: St John's wort is an effective antidepressant that can reduce tobacco withdrawal symptoms, but it is not known whether it assists cessation. Chromium assists weight loss and might limit post cessation weight gain. METHODS: In a factorial design, we randomised smokers stopping smoking to 900 mg St John's wort (SJW) active or placebo and also randomised them to 400 microm chromium or placebo daily. Treatment started 2 weeks prior to quit day and continued for 14 weeks. Participants and researchers were blind to treatment allocation. All participants received weekly behavioural support. The primary endpoints were biochemically confirmed prolonged abstinence and mean weight gain in abstinent smokers 4 weeks after quitting. RESULTS: 6/71 (8.5%) participants on active SJW and 9/72 (12.5%) on placebo achieved prolonged abstinence at 4 weeks, an odds ratio (OR) (95% confidence interval) of 0.65 (0.22-1.92). At 6 months, 3 (4.2%) SJW active and 6 (8.3%) SJW placebo participants were still abstinent, an OR of 0.49 (0.12-2.02). Among these participants, the mean difference in weight gain between active chromium and placebo was -0.8 1kg (-3.79 to 2.18) at 4 weeks and -3.88 kg (-12.13 to 4.38) at 6 months. CONCLUSIONS: Taking together the absolute quit rates, the small difference between active and placebo, and lack of effects on withdrawal shows that SJW is ineffective for smoking cessation. Insufficient people stopped smoking to properly test the efficacy of chromium in preventing weight gain, but the point estimate indicates a potentially worthwhile benefit.
Assuntos
Compostos de Cromo/uso terapêutico , Hypericum , Abandono do Hábito de Fumar/métodos , Aumento de Peso/efeitos dos fármacos , Adulto , Ansiedade/prevenção & controle , Ansiedade/psicologia , Depressão/prevenção & controle , Depressão/psicologia , Suplementos Nutricionais , Educação , Determinação de Ponto Final , Etnicidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fumar/psicologia , Fatores Socioeconômicos , Síndrome de Abstinência a Substâncias/prevenção & controleRESUMO
AIMS: The aim of this work was to study the effectiveness of (32)P-chromic phosphate colloids ((32)P-CP), by stromal injection during cardiac-esophageal carcinoma resection, in the prevention and treatment of minute lymphatic metastasis. METHODS: A multipointed infiltrative injection was done on 91 patients with clinically diagnosed cardiac-esophageal carcinoma to the adipose connective tissues of the corresponding bed of the resected lesion or retroperitonial wall, or tissues neighboring the left gastric artery, abdominal aorta, fenestra of aortic arch, pulmonary hilum, and superior mediastinum following the resection of a tumor. For patients with nonresectable lesions, a multipointed superficial injection of (32)P-CP-diluted solution was administered to the tumor and its surrounding invaded tissue, gastric artery, and the mediastinal adipose connective tissue. The dosage of (32)P-CP was 296 ~ 370 MBq/10 mL (8 ~ 10 mCi/10 mL). A simple operative group of 99 cases with clinically diagnosed cardiac-esophageal carcinoma, but without being given an injection of (32) P-CP, served as the control. Survival curves between the 2 groups were obtained using the Kaplan-Meier method and were compared by a log-rank test. The differences in complications following the operation, the positive rate of lymph nodes (LN), the rate of LN metastasis, and the survival rate following the operation between the 2 groups were determined by conducting a monofactorial analysis by a chi(2) test. RESULTS: No operative deaths occurred in either group. The incidences of perioperative complications were not different statistically between the 2 groups (p > 0.05). The rate of lymph node metastasis, as well as the incidences of mediastinum, supraclavicle, and abdominal lymph node metastasis, showed that there were prominent statistical differences between the 2 groups (p < 0.05). A Kaplan-Meier analysis showed that there was a significant difference between the operative plus irradiation group, compared with the simple operative group (p = 0.0085). CONCLUSIONS: Stromal medication with (32)P-CP during a cardiac-esophageal carcinoma resection is a simple and safe procedure for controlling postoperative lymphatic metastasis and revealed a very fair clinical effectiveness in improving both medium- and long-term survival rates in patients.
Assuntos
Compostos de Cromo/farmacologia , Compostos de Cromo/uso terapêutico , Neoplasias Cardíacas/patologia , Neoplasias Cardíacas/cirurgia , Fosfatos/farmacologia , Fosfatos/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Neoplasias Cardíacas/complicações , Humanos , Metástase Linfática/patologia , Metástase Linfática/prevenção & controle , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Taxa de Sobrevida , Fatores de TempoAssuntos
Compostos Radiofarmacêuticos/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Ascite/radioterapia , Neoplasias Ósseas/radioterapia , Neoplasias Ósseas/secundário , Compostos de Cromo/uso terapêutico , Humanos , Hipertireoidismo/radioterapia , Radioisótopos do Iodo/uso terapêutico , Linfoma não Hodgkin/radioterapia , Compostos Organometálicos/uso terapêutico , Compostos Organofosforados/uso terapêutico , Dor/etiologia , Dor/radioterapia , Isolamento de Pacientes/normas , Fosfatos/uso terapêutico , Derrame Pleural Maligno/radioterapia , Policitemia Vera/radioterapia , Proteção Radiológica/normas , Compostos Radiofarmacêuticos/efeitos adversos , Iodeto de Sódio/uso terapêutico , Radioisótopos de Estrôncio/uso terapêutico , Trombocitopenia/radioterapia , Neoplasias da Glândula Tireoide/radioterapia , Radioisótopos de Ítrio/uso terapêuticoRESUMO
The cation [Cr(3)O(propionate)(6)(H(2)O)(3)](+) has recently been found by oral or intravenous administration to increase insulin sensitivity and improve serum lipids in healthy and type 2 diabetic model rats. Serum insulin concentrations and, hence, insulin sensitivity are in part responsible for the relationship between diet and the incidence of colorectal cancer. This strongly suggested that the synthetic cation, which in vitro is able to stimulate insulin receptor tyrosine kinase activity in a fashion similar to the oligopeptide chromodulin, could influence the incidence of colorectal cancer. Consequently, the effects of the cation on the inhibition of colon tumorigenesis induced by 1,2-dimethylhydrazine in male Sprague Dawley rats were examined. Gavage administration of aqueous solutions of the complex (1000 microg Cr/kg body mass daily for 6 months) resulted in significantly decreased colon tumor incidence (P<0.003).
Assuntos
Biomimética , Cátions , Linhagem Celular Tumoral/efeitos dos fármacos , Compostos de Cromo , Neoplasias Colorretais , 1,2-Dimetilidrazina/farmacologia , Animais , Peso Corporal , Carcinógenos/farmacologia , Cátions/química , Cátions/farmacologia , Cátions/uso terapêutico , Compostos de Cromo/química , Compostos de Cromo/farmacologia , Compostos de Cromo/uso terapêutico , Neoplasias Colorretais/induzido quimicamente , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/prevenção & controle , Dieta , Feminino , Humanos , Masculino , Ratos , Ratos Sprague-DawleyRESUMO
PURPOSE: To conduct a prospective study of intraperitoneal radioactive chromic phosphate (32P) versus cyclophosphamide-cisplatin (CP) in women with early ovarian cancer at high risk for recurrence (International Federation of Gynecology and Obstetrics stage Ia or Ib grade 3 or Ic or stage II, no macroscopic residual disease) and to compare cumulative incidence of recurrence, overall survival, and relative toxicity. MATERIALS AND METHODS: A total of 251 patients were randomly assigned to treatment with 32P or CP. Twenty-two (8.7%) were ineligible following centralized pathology review. Of the 229 patients included in the analysis, 110 received 32P, and 119 received CP. RESULTS: The cumulative incidence of recurrence at 10 years was 35% (95% CI, 27% to 45%) for patients receiving 32P and 28% (95% CI, 21% to 38%) for those receiving CP. Patients receiving CP had a recurrence rate 29% lower than that of those receiving 32P (P =.15, two-tail test). The death rate for patients treated with CP was 17% lower than that for patients treated with 32P (difference not significant). Combining both arms, the 10-year cumulative incidence of recurrence for all stage I patients was 27% (95% CI, 20% to 34%) compared with 44% (95% CI, 32% to 56%) for stage II patients (P =.01). Both regimens were reasonably well tolerated, but problems with inadequate distribution (7%) and small-bowel perforation (3%) make the otherwise less toxic 32P less acceptable. CONCLUSION: Although there are no statistically significant differences in survival, the lower cumulative recurrence seen with CP and complications of 32P administration make platinum-based combinations the preferred adjuvant therapy for early ovarian cancer patients at high-risk for recurrence.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Compostos de Cromo/uso terapêutico , Neoplasias Ovarianas/terapia , Fosfatos/uso terapêutico , Adenocarcinoma Mucinoso/mortalidade , Adenocarcinoma Mucinoso/patologia , Adenocarcinoma Mucinoso/terapia , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma Endometrioide/mortalidade , Carcinoma Endometrioide/patologia , Carcinoma Endometrioide/terapia , Quimioterapia Adjuvante , Compostos de Cromo/administração & dosagem , Compostos de Cromo/efeitos adversos , Cisplatino/administração & dosagem , Terapia Combinada , Ciclofosfamida/administração & dosagem , Cistadenocarcinoma Seroso/mortalidade , Cistadenocarcinoma Seroso/patologia , Cistadenocarcinoma Seroso/terapia , Intervalo Livre de Doença , Feminino , Humanos , Injeções Intraperitoneais , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/epidemiologia , Neoplasias Ovarianas/mortalidade , Neoplasias Ovarianas/patologia , Fosfatos/administração & dosagem , Fosfatos/efeitos adversos , Radioisótopos de Fósforo , Estudos Prospectivos , Taxa de Sobrevida , Resultado do TratamentoRESUMO
PURPOSE: The objectives of this prospective randomized study of consolidation therapy were to evaluate recurrence-free survival (RFS), overall survival (OS), and the morbidity of intraperitoneal (IP) chromic phosphate suspension (32P) therapy in patients with stage III epithelial ovarian carcinoma who have no detectable evidence of disease at the second-look laparotomy (SLL) procedure after primary chemotherapy. PATIENTS AND METHODS: In a multi-institution clinical cooperative trial, 202 eligible patients with a negative SLL were randomly selected to receive either 15 mCi IP 32P (n = 104) or no further therapy (NFT; n = 98). RESULTS: With a median follow-up of 63 months in living patients, 68 patients in the IP 32P group (65%) and 63 patients in the NFT group (64%) have developed tumor recurrence. The relative risk of recurrence is 0.90 (IP 32P to NFT) (90% confidence interval [CI], 0.68 to 1.19). The 5-year RFS rate is 42% and 36% for the IP 32P and NFT groups, respectively; the difference is not statistically significant (log-rank test, P =.27). There was no statistically significant difference in OS (P =.19). The relative risk of death is 0.85 (IP 32P to NFT) (90% CI, 0.62 to 1.16). Sixteen patients (8%) experienced grade 3 or 4 adverse effects, with eight in each respective group. CONCLUSION: Intraperitoneal chromic phosphate did not decrease the risk of relapse or improve survival for patients with stage III epithelial ovarian cancer after a negative SLL. Despite complete pathologic remission at SLL after initial surgery and platinum-based chemotherapy, 61% of stage III ovarian cancer patients had tumor recurrence within 5 years of negative SLL. This indicates a need for more effective initial therapy and further studies of consolidation therapy.
Assuntos
Carcinoma/radioterapia , Neoplasias Ovarianas/radioterapia , Radioisótopos de Fósforo/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma/patologia , Carcinoma/cirurgia , Distribuição de Qui-Quadrado , Compostos de Cromo/uso terapêutico , Terapia Combinada , Feminino , Humanos , Infusões Parenterais , Laparotomia , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/cirurgia , Fosfatos/uso terapêutico , Modelos de Riscos Proporcionais , Estudos Prospectivos , Análise de Sobrevida , Resultado do TratamentoRESUMO
During the last decade, intraperitoneal injection of phosphorus-32 chromic phosphate (P-32 CP) has been used principally for its initial intended purpose, the palliative management of malignant ascites. The authors describe a patient with a stage IIIB well-differentiated extraovarian peritoneal serous papillary adenocarcinoma. As a palliative treatment for malignant ascites, P-32 CP was instilled intraabdominally eight times. Adverse effects were limited to the third instillation, when abdominal pain occurred as a result of leakage of the P-32 CP in the subcutaneous tissue. The P-32 CP instillations reduced the frequency of paracentesis for almost 1 year, until disease progression prevented palliation. Considering the few palliative options, there could be more widespread use of P-32 CP as a palliative treatment for patients with malignant ascites caused by ovarian cancer or extraovarian peritoneal adenocarcinoma. However, intraperitoneal P-32 CP is not without potential intestinal complications, which must be considered before it is recommended.
Assuntos
Ascite/radioterapia , Compostos de Cromo/administração & dosagem , Compostos de Cromo/uso terapêutico , Cuidados Paliativos/métodos , Neoplasias Peritoneais/radioterapia , Fosfatos/administração & dosagem , Fosfatos/uso terapêutico , Adenocarcinoma Papilar/complicações , Adenocarcinoma Papilar/radioterapia , Adulto , Ascite/etiologia , Ascite/cirurgia , Fracionamento da Dose de Radiação , Feminino , Seguimentos , Humanos , Injeções Intraperitoneais , Neoplasias Ovarianas/radioterapia , Paracentese , Neoplasias Peritoneais/complicações , Compostos Radiofarmacêuticos/administração & dosagem , Compostos Radiofarmacêuticos/uso terapêutico , Resultado do TratamentoRESUMO
The principal medical consequence of haemophilia is the development of arthropathy, initiated by a haemarthrosis giving rise to chronic synovitis. Traditional methods of synovectomy include open excision and arthroscopy each of which require substantial amounts of clotting factor concentrate for several weeks, and in the case of open synovectomy, is often associated with loss of range of motion and arthrofibrosis. Radiosynovectomy, the intra-articular injection of low penetration radiocolloids, has been utilized outside the United States for over 20 years. Since 1988, our centre has performed 170 radiosynovectomies utilizing 32P chromic phosphate (32P). This study reports results of 130 32P radiosyovectomies with an average follow-up of 36.5 months (6-140 months). For primary procedures, excellent and good results (haemarthrosis reduction from 75 to 100%) were obtained in 79.2% of cases at 6 months to 8 years. For repeat procedures a combination of excellent and good results were obtained in 62.4% of cases at 6 months to 3 years. Regression analysis showed no correlation between results and age or degree of arthropathy. Radiation was well contained within the joint. There were no observed or identified complications. The procedure is highly cost effective in comparison to open surgical or arthroscopic synovectomy.
Assuntos
Compostos de Cromo/administração & dosagem , Hemofilia A/complicações , Fosfatos/administração & dosagem , Radioisótopos de Fósforo/administração & dosagem , Sinovectomia , Sinovite/tratamento farmacológico , Adolescente , Adulto , Fatores Etários , Criança , Pré-Escolar , Compostos de Cromo/uso terapêutico , Doença Crônica , Terapia Combinada , Seguimentos , Hemartrose/complicações , Hemartrose/tratamento farmacológico , Hemartrose/etiologia , Hemofilia A/patologia , Hemofilia A/terapia , Hemorragia , Humanos , Injeções Intra-Articulares , Pessoa de Meia-Idade , Fosfatos/uso terapêutico , Radioisótopos de Fósforo/uso terapêutico , Estudos Retrospectivos , Medição de Risco , Sinovite/etiologia , Sinovite/patologia , Resultado do TratamentoRESUMO
OBJECTIVE: To review the drug treatments and some of the popular, nontraditional remedies now available for type 2 diabetes mellitus, as well as selected investigational agents; to describe each medication's place in the overall approach to treatment. DATA SOURCES: English-language journals, abstracts, review articles, and newspaper accounts. DATA SYNTHESIS: In the past five years, there has been tremendous progress in the pharmacotherapy of diabetes, particularly type 2 diabetes. Several new agents have entered the clinical arena, and many more are in the late stages of investigation leading to approval. Sulfonylureas stimulate the production and release of insulin; these drugs must be used in patients with an intact pancreas. The meglitinides are nonsulfonylurea agents that are also insulin secretagogues. Unlike the sulfonylureas, repaglinide appears to require the presence of glucose to close the adenosine triphosphate-sensitive potassium channels and induce calcium influx. Metformin reduces hepatic glucose production in some patients and increases peripheral glucose utilization, but its use is hampered by a high percentage of adverse reactions. Disaccharidase inhibitors effectively compensate for the defective early-phase insulin release by slowing the production of sugars from carbohydrates. Thiazolidinediones appear to activate peroxisome proliferator-activated receptor gamma, which is involved in the metabolism of lipids. Short-acting insulin and the role of weight-loss agents are also discussed. CONCLUSIONS: The availability of new options for diabetes therapy provides a chance for successful therapy in a larger number of patients. However, it is important to consider how much true benefit these new forms of treatment will have on the diabetic community. The best choice for a patient remains controversial.
Assuntos
Biguanidas/uso terapêutico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Compostos de Sulfonilureia/uso terapêutico , Tiazolidinedionas , Fármacos Antiobesidade/uso terapêutico , Biguanidas/efeitos adversos , Cromanos/uso terapêutico , Compostos de Cromo/administração & dosagem , Compostos de Cromo/uso terapêutico , Terapias Complementares , Diabetes Mellitus Tipo 2/terapia , Dietoterapia , Dissacaridases/antagonistas & inibidores , Humanos , Insulina/metabolismo , Insulina/uso terapêutico , Leptina/uso terapêutico , Tiazóis/uso terapêutico , Troglitazona , Reino Unido , Compostos de Vanádio/efeitos adversos , Compostos de Vanádio/uso terapêuticoRESUMO
We report the nonoperative treatment of a recurrent, multilevel spinal aneurysmal bone cyst by injection of 32P chromic phosphate colloid into the cyst. The patient was then followed up with serial CT examinations, which showed stabilization and progressive ossification within the lesion. The rationale, alternatives, and possible contraindications to radionuclide ablation of spinal aneurysmal bone cysts are discussed.
Assuntos
Cistos Ósseos Aneurismáticos/radioterapia , Compostos de Cromo/uso terapêutico , Fosfatos/uso terapêutico , Radioisótopos de Fósforo/uso terapêutico , Compostos Radiofarmacêuticos/uso terapêutico , Doenças da Coluna Vertebral/radioterapia , Adolescente , Cistos Ósseos Aneurismáticos/diagnóstico , Cistos Ósseos Aneurismáticos/diagnóstico por imagem , Feminino , Humanos , Injeções , Imageamento por Ressonância Magnética , Doenças da Coluna Vertebral/diagnóstico , Doenças da Coluna Vertebral/diagnóstico por imagem , Tomografia Computadorizada por Raios XRESUMO
Malignant pericardial effusion is usually treated only when signs of cardiac tamponade develop. Several methods of treatment have been reported with an overall response rate of approximately 75%. Since our initial study using intrapericardial 32P-colloid instillation as a treatment modality for pericardial effusion demonstrated a significant higher response rate, this study was conducted to further evaluate the efficacy of intrapericardial 32P-colloid in terms of response rates and duration of remissions. Intrapericardial instillation of 185-370 MBq (5-10 mCi) 32P-colloid in 36 patients with malignant pericardial effusion resulted in a complete remission rate of 94.5% (34 patients) whereas two patients did not respond to treatment due to a foudroyant formation of pericardial fluid. The median duration time was 8 months. No side-effects were observed. These results suggest that intrapericardial instillation of 32P-colloid is a simple, reliable and safe treatment strategy for patients with malignant pericardial effusions. Therefore, since further evidence is provided that 32P-colloid is significantly more effective than external radiation or non-radioactive sclerosing agents, this treatment modality should be considered for the management of malignant pericardial effusion.